Skip to content
OpenCapital
Get started

Insulet PODD Cash Provided by (Used in) Operating Activity, Including Discontinued Operation

Cash Provided by (Used in) Operating Activity, Including Discontinued Operation at other companies

Medtronic logo
MedtronicMDT
——
West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
——

Other financials

Income statement

See full
Revenue$761.7M+33.9%
Gross profit$529.0M+29.3%
Operating income$122.1M+37.5%
Net income$91.1M+157%
EPS (diluted)$1.30+160%

Balance sheet

See full
Cash & equivalents$480.4M-62.6%
Total debt$969.7M-45.5%
Total equity$1.3B-2.1%
Total assets$3.0B-15.1%

Cash flow

See full
Operating cash flow$113.8M+78.4%
CapEx$24.3M+97.6%
Free cash flow$89.5M+73.8%

Valuation

See full
Market cap$10.1B-19.9%
Enterprise value$10.59B-19.4%
P/E33.3×+2.0×
P/S3.5×-2.3×

Profitability

See full
Gross margin71%+0.6pp
Operating margin17.5%+2.0pp
Net margin10.4%-7.9pp
FCF margin14.3%+1.1pp

Returns & leverage

See full
Return on equity23%-14.9pp
Debt / equity0.7×-0.6×
Current ratio2.5×-2.0×

Where this comes from

Reported directly by Insulet in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The official record: Insulet’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Insulet's cash provided by (used in) operating activity, including discontinued operation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Insulet's cash provided by (used in) operating activity, including discontinued operation?
Insulet (PODD) reported cash provided by (used in) operating activity, including discontinued operation of $113.8M in Q1 2026.
How has Insulet's cash provided by (used in) operating activity, including discontinued operation changed year-over-year?
Insulet's cash provided by (used in) operating activity, including discontinued operation increased by 78.4% year-over-year, from $63.8M to $113.8M.
What is the long-term trend for Insulet's cash provided by (used in) operating activity, including discontinued operation?
Over 3 years (2022 to 2025), Insulet's cash provided by (used in) operating activity, including discontinued operation has grown at a 68.5% compound annual growth rate (CAGR), from $119M to $569.3M.